FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978473277> ?p ?o ?g. }

• W2978473277 endingPage "v252" @default.
• W2978473277 startingPage "v251" @default.
• W2978473277 abstract "Abstract Background Checkpoint inhibitors (CPIs) have transformed treatment of many malignancies. However, to date, response to checkpoint blockade in unselected gastrointestinal (GI) cancers has been disappointing. Tumours which display a non-T-cell inflamed phenotype such as mismatch repair proficient (MMRp) oesophagogastric (OG) and colorectal cancers (CRC) respond less frequently to CPIs. Changes in tumour expression of antigens and increased immune infiltrate are associated with improved response to CPIs. Epigenetic modulation of tumours using HDAC inhibitors can lead to increased tumour antigen presentation, immune cell infiltrates and thereby may increase the chance of response to immunotherapy. Trial design EMERGE is designed to evaluate the safety and efficacy of domatinostat, a selective class 1 histone deacetylase inhibitor in combination with avelumab, an anti-PD-L1 monoclonal antibody in patients with previously treated, inoperable or metastatic MMRp OG and CRC. The trial is conducted in 2 stages: Phase IIA will establish a safe and tolerated dose of domatinostat plus avelumab using a 3 + 3 dose finding design and escalating doses of domatinostat will be examined, dosing of avelumab will remain constant. The phase IIB will use a Simon two stage optimal design to assess efficacy of the combination in achieving radiological response according to RECIST v1.1. The primary endpoint of the phase IIB is best objective response rate (ORR) at 6 months. To rule out an ORR of 5% in the CRC cohort, while aiming for 20%, 1/10 and 4/29 responses are required in the 1st and 2nd stages respectively. To rule out an ORR of 15% in the OG cohort while aiming for 35%, 2/9 and 9/34 responses are required in the 1st and 2nd stages respectively with a 1-sided alpha of 5% and 80% power. Secondary endpoints are DoOR, PFS, OS, DCR, safety and tolerability. Exploratory objectives will investigate dynamic changes in expression of tumour associated antigens and immune infiltrates in baseline and on-treatment biopsies and correlate baseline tumour characteristics and circulating biomarkers with tumour response and survival. Recruitment commenced in January 2019, 83 patients will be recruited over 3 years. (ClinTrials.gov. ID: NCT03812796). Legal entity responsible for the study Royal Marsden Hospital NHS Foundation Trust. Funding Royal Marsden Hospital NHS Foundation Trust, 4SC. Disclosure M. Hubank: Research grant / Funding (self), Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (self), Research grant / Funding (institution): Roche Diagnostics; Research grant / Funding (self), Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (self), Research grant / Funding (institution): Guardant Health; Research grant / Funding (self), Research grant / Funding (institution): Celgene; Research grant / Funding (self), Research grant / Funding (institution): Eli Lilley. I. Chau: Honoraria (self): Eli-Lilly; Research grant / Funding (institution): Eli-Lilly; Research grant / Funding (institution): Janssen-Cilag; Research grant / Funding (institution): Sanofi Oncology; Research grant / Funding (institution): Merck-Serono; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Bristol Meyers Squibb; Advisory / Consultancy: MSD; Advisory / Consultancy: Bayer; Advisory / Consultancy: Roche; Advisory / Consultancy: Merck-Serono; Advisory / Consultancy: Five Prime Therapeutics; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Oncologie International; Advisory / Consultancy: Pierre Fabre. N. Starling: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Pfizer; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Eli Lilly; Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: Roche; Honoraria (self): AstraZeneca; Honoraria (self): Eli Lilly; Honoraria (self): Merck; Honoraria (self): Servier; Advisory / Consultancy: Pfizer; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Servier. D. Cunningham: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): 4SC; Research grant / Funding (institution): Clovis; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Merck. All other authors have declared no conflicts of interest." @default.
• W2978473277 created "2019-10-10" @default.
• W2978473277 creator A5004047300 @default.
• W2978473277 creator A5004867407 @default.
• W2978473277 creator A5024169587 @default.
• W2978473277 creator A5032096052 @default.
• W2978473277 creator A5032300804 @default.
• W2978473277 creator A5039870429 @default.
• W2978473277 creator A5051974926 @default.
• W2978473277 creator A5056345420 @default.
• W2978473277 creator A5063249127 @default.
• W2978473277 creator A5063650915 @default.
• W2978473277 creator A5075765455 @default.
• W2978473277 creator A5077300810 @default.
• W2978473277 creator A5079423521 @default.
• W2978473277 date "2019-10-01" @default.
• W2978473277 modified "2023-10-16" @default.
• W2978473277 title "EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers" @default.
• W2978473277 doi "https://doi.org/10.1093/annonc/mdz246.147" @default.
• W2978473277 hasPublicationYear "2019" @default.
• W2978473277 type Work @default.
• W2978473277 sameAs 2978473277 @default.
• W2978473277 citedByCount "3" @default.
• W2978473277 countsByYear W29784732772020 @default.
• W2978473277 countsByYear W29784732772021 @default.
• W2978473277 countsByYear W29784732772023 @default.
• W2978473277 crossrefType "journal-article" @default.
• W2978473277 hasAuthorship W2978473277A5004047300 @default.
• W2978473277 hasAuthorship W2978473277A5004867407 @default.
• W2978473277 hasAuthorship W2978473277A5024169587 @default.
• W2978473277 hasAuthorship W2978473277A5032096052 @default.
• W2978473277 hasAuthorship W2978473277A5032300804 @default.
• W2978473277 hasAuthorship W2978473277A5039870429 @default.
• W2978473277 hasAuthorship W2978473277A5051974926 @default.
• W2978473277 hasAuthorship W2978473277A5056345420 @default.
• W2978473277 hasAuthorship W2978473277A5063249127 @default.
• W2978473277 hasAuthorship W2978473277A5063650915 @default.
• W2978473277 hasAuthorship W2978473277A5075765455 @default.
• W2978473277 hasAuthorship W2978473277A5077300810 @default.
• W2978473277 hasAuthorship W2978473277A5079423521 @default.
• W2978473277 hasBestOaLocation W29784732771 @default.
• W2978473277 hasConcept C104317684 @default.
• W2978473277 hasConcept C107038049 @default.
• W2978473277 hasConcept C121608353 @default.
• W2978473277 hasConcept C123079801 @default.
• W2978473277 hasConcept C126322002 @default.
• W2978473277 hasConcept C138885662 @default.
• W2978473277 hasConcept C143998085 @default.
• W2978473277 hasConcept C203014093 @default.
• W2978473277 hasConcept C2991678113 @default.
• W2978473277 hasConcept C41091548 @default.
• W2978473277 hasConcept C502942594 @default.
• W2978473277 hasConcept C526805850 @default.
• W2978473277 hasConcept C542804219 @default.
• W2978473277 hasConcept C54355233 @default.
• W2978473277 hasConcept C71924100 @default.
• W2978473277 hasConcept C86803240 @default.
• W2978473277 hasConcept C8891405 @default.
• W2978473277 hasConceptScore W2978473277C104317684 @default.
• W2978473277 hasConceptScore W2978473277C107038049 @default.
• W2978473277 hasConceptScore W2978473277C121608353 @default.
• W2978473277 hasConceptScore W2978473277C123079801 @default.
• W2978473277 hasConceptScore W2978473277C126322002 @default.
• W2978473277 hasConceptScore W2978473277C138885662 @default.
• W2978473277 hasConceptScore W2978473277C143998085 @default.
• W2978473277 hasConceptScore W2978473277C203014093 @default.
• W2978473277 hasConceptScore W2978473277C2991678113 @default.
• W2978473277 hasConceptScore W2978473277C41091548 @default.
• W2978473277 hasConceptScore W2978473277C502942594 @default.
• W2978473277 hasConceptScore W2978473277C526805850 @default.
• W2978473277 hasConceptScore W2978473277C542804219 @default.
• W2978473277 hasConceptScore W2978473277C54355233 @default.
• W2978473277 hasConceptScore W2978473277C71924100 @default.
• W2978473277 hasConceptScore W2978473277C86803240 @default.
• W2978473277 hasConceptScore W2978473277C8891405 @default.
• W2978473277 hasLocation W29784732771 @default.
• W2978473277 hasOpenAccess W2978473277 @default.
• W2978473277 hasPrimaryLocation W29784732771 @default.
• W2978473277 hasRelatedWork W1968431555 @default.
• W2978473277 hasRelatedWork W2012887294 @default.
• W2978473277 hasRelatedWork W2577548098 @default.
• W2978473277 hasRelatedWork W2802712046 @default.
• W2978473277 hasRelatedWork W2999641105 @default.
• W2978473277 hasRelatedWork W3031852375 @default.
• W2978473277 hasRelatedWork W3112940496 @default.
• W2978473277 hasRelatedWork W3121877887 @default.
• W2978473277 hasRelatedWork W3140189487 @default.
• W2978473277 hasRelatedWork W3197240869 @default.
• W2978473277 hasVolume "30" @default.
• W2978473277 isParatext "false" @default.
• W2978473277 isRetracted "false" @default.
• W2978473277 magId "2978473277" @default.
• W2978473277 workType "article" @default.